Amidst chaotic CDC meetings, speculation grows that RFK Jr. may overhaul the U.S. vaccine schedule, aligning it with Denmark’s, sparking concern among health experts.
Story Snapshot
- RFK Jr.’s appointees delay hepatitis B vaccine decision amid confusion.
- Denmark’s lighter vaccine schedule sparks speculation of U.S. adoption.
- Experts warn that reducing vaccines could undermine public health.
ACIP Meeting Chaos and Vaccine Delays
During the December 2025 CDC meeting, chaos erupted as RFK Jr.’s handpicked advisers postponed the decision on hepatitis B vaccinations for infants. The delay came amid confusion over last-minute changes and anti-vaccine rhetoric, with racial innuendo and selective evidence further complicating proceedings. This postponement follows an earlier September meeting where similar confusion led to the reversal of the MMRV coverage decision, setting a concerning precedent.
Day one of the meeting ended without a vote, leaving many experts frustrated. Critics argue that the committee, now filled with RFK Jr.’s appointees, is pushing an anti-vaccine agenda that undermines established scientific evidence. The agenda hinted at future discussions comparing the U.S. and Denmark’s vaccine schedules, fueling speculation about potential changes, despite no formal proposal currently existing.
Comparing U.S. and Denmark’s Vaccine Schedules
Denmark’s vaccine schedule, which delays certain vaccines and doesn’t routinely administer hepatitis B shots to infants unless at high risk, contrasts sharply with the U.S. schedule. The U.S. has successfully reduced hepatitis B cases through early vaccinations. Critics fear that adopting Denmark’s model could increase the risk of hepatitis B resurgence and disrupt other vaccine schedules like DTaP and Hib, which are crucial for preventing childhood diseases.
RFK Jr., as Secretary of Health and Human Services, has shifted the Advisory Committee on Immunization Practices (ACIP) from an evidence-based to a more skeptical composition. This change has allowed for the reconsideration of settled vaccines without new data, raising alarms among public health experts and advocacy groups. The speculation of a Denmark swap has stirred significant debate, highlighting the tension between scientific consensus and vaccine skepticism.
Implications and Expert Concerns
The postponement of the hepatitis B vote maintains the status quo temporarily but risks eroding trust in the ACIP. Experts like Grant Paulsen of the Pediatric Infectious Diseases Society question the rationale behind revisiting vaccine safety without new publications. They warn of the potential public health risks, especially for newborns who are most vulnerable to hepatitis B transmission from their mothers.
Critics, including CDC scientists and medical liaisons, emphasize that the birth dose of the hepatitis B vaccine is evidence-based and race-neutral, crucial for preventing lifelong infections. The possibility of a shift toward Denmark’s schedule could undermine decades of progress in public health and strain the infrastructure by revisiting settled science.
